2009-11-11 15:36:05 -

Adamis Pharmaceuticals Corporation : (OTCBB: ADMP), announced today that its wholly owned subsidiary, Adamis Labs has now secured distribution contracts and initial stocking orders from the three major wholesalers of prescription drugs in the U.S. These three wholesalers distribute approximately 90 percent of U.S. drugs made by manufacturers. With the recent shipments of product, Adamis’ pre-filled epinephrine syringe

(Epinephrine Injection USP 1:1000 [0.3mg]) will be available to most pharmacies in the U.S. Since many of the major health insurance companies have classified Adamis’ pre-filled epinephrine syringe in Tier 1, (their lowest copay) Adamis can offer allergic patients the opportunity to purchase a low cost and potentially lifesaving medicine.
Dr. Dennis J Carlo, President and CEO of Adamis stated, “We are just laying the foundation to enable Adamis to capture a significant portion of the $200 million epinephrine market. We plan to hire a salesforce over the next few months to help raise awareness and accelerate sales growth of our epi syringe.”


About Adamis Pharmaceuticals

Adamis Pharmaceuticals has two wholly owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs expects to launch a series of niche prescription products in the allergy and respiratory therapeutic area, beginning with the pre-filled epinephrine syringe product. Adamis Viral Therapies is focused on the development of patented, proprietary vaccine technology that Adamis believes may have the capability of generating a broad-based immunity for both B Cells (antibody) and T cells (cell mediated immunity). If successful, Adamis’ technology could lead to the development of new vaccines against a multitude of viruses, including chronic hepatitis and all forms of influenza.


Forward Looking Statements

Any statements in this press release regarding Adamis’ business, products or potential products that are not historical facts may be considered “forward-looking statements.” The company has based these statements on management’s current expectations, assumptions and estimates. Such statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the company’s control. Predicting financial and commercial results of the launch of a new product such as the Epi PFS is inherently uncertain and subject to the risk of inaccuracy. You should review the company’s discussion of risk factors and other disclosures in Adamis’ filings with the Securities and Exchange Commission, including the most recent annual report on Form 10-K filed by the company with the SEC. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made.



Investor Relations Contact:Capital Group Communications, Inc.Mark

Bernhard, mark@capitalgc.com : mailto:mark@capitalgc.com Mark

Gundy, mark.gundy@capitalgc.com : mailto:mark.gundy@capitalgc.com Tel:

415.332.7200